Annual Cash & Cash Equivalents
$32.75 M
-$189.82 M-85.29%
December 31, 2022
Summary
- As of February 9, 2025, TCRR annual cash & cash equivalents is $32.75 million, with the most recent change of -$189.82 million (-85.29%) on December 31, 2022.
- During the last 3 years, TCRR annual cash & cash equivalents has fallen by -$32.55 million (-49.85%).
Performance
TCRR Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$14.45 M
-$18.30 M-55.88%
March 31, 2023
Summary
- As of February 9, 2025, TCRR quarterly cash and cash equivalents is $14.45 million, with the most recent change of -$18.30 million (-55.88%) on March 31, 2023.
- Over the past year, TCRR quarterly cash and cash equivalents has dropped by -$59.67 million (-80.51%).
Performance
TCRR Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
TCRR Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -85.3% | -80.5% |
| 3 y3 years | -49.9% | -53.5% |
| 5 y5 years | +65.3% | - |
TCRR Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -85.3% | at low | -93.5% | at low |
| 5 y | 5-year | -85.3% | at low | -94.5% | at low |
| alltime | all time | -85.3% | -75.6% | -94.5% | at low |
TCR2 Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2023 | - | $14.45 M(-55.9%) |
| Dec 2022 | $32.75 M(-85.3%) | $32.75 M(-39.4%) |
| Sep 2022 | - | $54.01 M(+22.2%) |
| Jun 2022 | - | $44.21 M(-40.3%) |
| Mar 2022 | - | $74.12 M(-66.7%) |
| Dec 2021 | $222.56 M(+136.4%) | $222.56 M(-15.2%) |
| Sep 2021 | - | $262.50 M(+5.5%) |
| Jun 2021 | - | $248.79 M(+14.0%) |
| Mar 2021 | - | $218.28 M(+131.8%) |
| Dec 2020 | $94.16 M | $94.16 M(-7.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2020 | - | $101.61 M(+104.5%) |
| Jun 2020 | - | $49.70 M(+59.8%) |
| Mar 2020 | - | $31.09 M(-52.4%) |
| Dec 2019 | $65.30 M(+37.0%) | $65.30 M(+32.4%) |
| Sep 2019 | - | $49.32 M(+20.3%) |
| Jun 2019 | - | $40.98 M(-11.7%) |
| Mar 2019 | - | $46.41 M(-2.7%) |
| Dec 2018 | $47.67 M(+140.6%) | $47.67 M(-55.8%) |
| Sep 2018 | - | $107.77 M(+444.0%) |
| Dec 2017 | $19.81 M(+147.9%) | $19.81 M |
| Dec 2016 | $7.99 M | - |
FAQ
- What is TCR2 Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for TCR2 Therapeutics?
- What is TCR2 Therapeutics annual cash & cash equivalents year-on-year change?
- What is TCR2 Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for TCR2 Therapeutics?
- What is TCR2 Therapeutics quarterly cash and cash equivalents year-on-year change?
What is TCR2 Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of TCRR is $32.75 M
What is the all time high annual cash & cash equivalents for TCR2 Therapeutics?
TCR2 Therapeutics all-time high annual cash & cash equivalents is $222.56 M
What is TCR2 Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, TCRR annual cash & cash equivalents has changed by -$189.82 M (-85.29%)
What is TCR2 Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of TCRR is $14.45 M
What is the all time high quarterly cash and cash equivalents for TCR2 Therapeutics?
TCR2 Therapeutics all-time high quarterly cash and cash equivalents is $262.50 M
What is TCR2 Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, TCRR quarterly cash and cash equivalents has changed by -$59.67 M (-80.51%)